Mount Sinai researchers have identified how ovarian cancer tumors manipulate their environment to resist immunotherapy and discovered that blocking the molecule IL-4 could enhance treatment effectiveness. Their findings suggest that the FDA-approved drug dupilumab might be repurposed to improve outcomes for ovarian cancer patients.